High level IL-2 expression vectors using HIV LTR in human colon carcinoma cell line (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

High level IL-2 expression vectors using HIV LTR in human colon carcinoma cell line (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 38:A217 1997. Unique Identifier : AIDSLINE MED/97619013
Vasanwala FH; Tsang TC; Liu F; Clark PR; Luznick L; Stopeck AT; Akaporiaye ET; Hersh EM; Harris DT; Department of Microbiology and Immunology, University of; Arizona,Tucson, AZ 84721

Abstract: The success of IL-2 gene therapy is dependent on high expression of the gene product. Tumor cells transduced with IL-2 and intratumoral injection of IL-2 expressing plasmids result in effective antitumor activity in some tumors. We have developed two plasmid expression vectors by replacing the CMV promoter of Promega pCl neo with HIV-1 LTR and HIV-2 LTR, respectively and cloned the IL-2 gene downstream of them. Both were further modified by the addition of another transcriptional unit expressing the Tat gene, a potent transactivator of HIV transcription. The above plasmids were transfected into human colon carcinoma cell line, SW480, using lipofection and assayed for IL-2 production 48 hours later by ELISA. The levels of IL-2 produced by HIV-1 IL-2 plasmid and HIV-2 IL-2 plasmid were comparable to the pCI neo-IL-2 (CMV promoter) plasmid, while that of HIV-1 IL-2-Tat and HIV-2 IL-2-Tat was 3 fold and 3.5 fold higher respectively. The CMV promoter is widely used to drive the expression of genes in various cell types. A possible advantage of HIV LTR-Tat promoter is that they may give higher expression than CMV in some cell types. Future studies involve transfecting different carcinoma cell lines, fresh tumor cells and T lymphocytes to observe the IL-2 production profile.

Keywords: *Colonic Neoplasms/GENETICS *Genetic Vectors *HIV Long Terminal Repeat *Interleukin-2/GENETICS
971030
M97A1343

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .